Business
Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS. Patients enrolled were at high risk for open surgic
About this update from Artivion, Inc.
[{"type":"text","content":"30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal","length":157,"tagName":"p","attribs":{}},{"type":"text","content":"ATLANTA, May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS. Patients enrolled were at high risk for open surgical repair.","length":562,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Artivion, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Artivion, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":57,"url":"https://media.zenfs.com/en/prnewswire.com/9c706ade2059beb91e5927de844091ef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IDclkFr3MoZKf5vK0cCAAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9c706ade2059beb91e5927de844091ef","width":400,"height":57}},"href":"https://mma.prnewswire.com/media/1728034/Artivion_new_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Bradley Leshnower, Professor of Surgery and Director of Thoracic Aortic Surgery, Emory University, presented the data from the NEXUS US IDE trial in an abstract titled, Endovascular Aortic Arch Repair Using a Novel Single-Branch Arch Stent Graft for Chronic Dissection: 30-Day Outcomes of the TRIOMPHE FDA Pivotal Study. ","length":324,"tagName":"p"},{"type":"text","content":"The data demonstrate statistically significant improvement in clinical outcomes and device technical performance compared with the performance goals set forth in the FDA-approved investigational device exemption (IDE).","length":218,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"className":"prnpr10 prnpl2 prnvat prnsbtb0 prnrbrb0 prnsbbb0 prnsblb0","colspan":"1","rowspan":"1","val":[{"type":"text","content":"","length":0,"tagName":"p","attribs":{"class":"prnpr10 prnpl2 prnvat prnsbtb0 ...